肝动脉胆道瘘8例报告  

Hepatic Arteriobiliary Fistula:the Clinical Data of 8 Patients

作　　者：甄宇洋[1] 马驰[1] 刘奕山[1] 肖隆斌[1] 邓量[1] 梁力建[2] 

机构地区：[1]中山大学附属第一医院黄埔院区普外科 [2]中山大学附属第一医院肝胆外科,广东广州510700

出　　处：《中山大学学报（医学科学版）》2004年第1期F002-F003,共2页Journal of Sun Yat-Sen University:Medical Sciences

摘　　要：[目的]通过对肝动脉胆道瘘病例临床观察分析,探讨其发生原因、临床表现及防治措施。[方法]收集原中山医科大学附属第一医院1982-2001年肝动脉插管化疗和皮下灌注器进行肝动脉栓塞化疗肝癌308例,对发生肝动脉胆道瘘者进行临床分析。[结果]本组有8例出现肝动脉胆道瘘,发生率为2.6％,出现时间在2个月至2年半的长期化疗栓塞过程中。临床表现以腹痛为主,偶然出现呕吐、发热等。[结论]长时间肝动脉插管化疗、栓塞,肝动脉胆管壁缺血,高浓度化疗、栓塞药物反复刺激,以及肿瘤坏死等因素影响,可导致肝动脉胆道瘘的发生。[ Objective J To analyze the causes, clinical manifestation and therapy for hepatic arteriobiliary fistula(HABF). [Method] We collected the clinical data of 8 patients who suffered from hepatic arteriobiliary fistula in 308 cases of hepatocellular carcinoma treated with hepatic artery emboliza-tion and chemotherapy by subcutaneous infusing apparatus during 1982-2001. [Result] The incidence of hepatic arteriobiliary fistula was 2. 6% (8/308) . The range of occurring time was 2 to 30 months after the first embolization and chemotherapy. The manifestation of this complication includes abdominal pain, vomiting and fever etc. [Conclusion] HABF is a common complication after embolization of hepatocellular carcinoma through subcutaneous infusing tube, and may be the result of long-term artery embolization, irritation of chemotherapeutic agents and tumor necrosis after therapy.

关 键 词：肝动脉 胆道 胆瘘 皮下灌注器 化疗 肝癌 

分 类 号：R735.8[医药卫生—肿瘤]